CVC began its vaccine production efforts in 2020 and is working on a T-cell COVID-19 vaccine.
CVC’s vaccine is designed to induce immunity to both current and yet unknown variants of the SARS-CoV-2 virus, and – claims CVC – will act as an enhancer to existing vaccines currently available on the market.
“We are now working with individuals that are global experts in the use, application and formulation of vaccine adjuvants. We have been talking to them for quite a while now, and with the good progress we are making in the lab we are optimistic about the future,” says CVC CEO Dr Robert Feldman.
The multi-national collaboration will see the two organisations combine their efforts to formulate CVC’s vaccine candidate with adjuvants. Adjuvants are substances commonly used in vaccines that, says CVC, enhance the human body’s immune response.
“We are pleased to initiate a collaboration with CVC. This aims to advance the development of CVC’s SARS-CoV-2 T cell polypeptide antigen by providing VFI adjuvants and formulation expertise,” says Dr Patrice Dubois, Co-Founder and Scientific Director of VFI.
“VFI’s adjuvants have been shown to enhance the immunogenicity of other COVID-19 vaccine candidates in both preclinical and clinical studies, and will now be investigated in combination with CVC’s T cell antigen.”
CVC is developing a “unique”, proprietary COVID-19 cytotoxic T cell vaccine with University of Auckland, Callaghan Innovation, Scion, Ardigen, Fonterra, and University of Queensland.